GLP 1 Drug Biosimilar Market Size, Share, Trend Report 2026 to 2035
Market Segmentation:
GLP-1 Drug Biosimilar Market by Reference Biologic -
• Semaglutide Biosimilar
• Liraglutide Biosimilar
• Exenatide Biosimilar
• Dulaglutide Biosimilar
GLP-1 Drug Biosimilar Market by Formulation -
• Injectable Pen
• Oral Tablet
• Patch & Implant
GLP-1 Drug Biosimilar Market by Distribution -
• Retail Pharmacy
• Mail-Order & Specialty Pharmacy
• Hospital & Clinic
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GLP-1 Drug Biosimilar Market Snapshot
Chapter 4. Global GLP-1 Drug Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035
4.8. Global GLP-1 Drug Biosimilar Market Penetration & Growth Prospect Mapping (US$ Mn), 2025-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2025)
4.10. Use/impact of AI on GLP-1 DRUG BIOSIMILAR MARKET Industry Trends
Chapter 5. GLP-1 Drug Biosimilar Market Segmentation 1: By Reference Biologic, Estimates & Trend Analysis
5.1. Market Share by Reference Biologic, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Reference Biologic:
5.2.1. Semaglutide Biosimilar
5.2.2. Liraglutide Biosimilar
5.2.3. Exenatide Biosimilar
5.2.4. Dulaglutide Biosimilar
Chapter 6. GLP-1 Drug Biosimilar Market Segmentation 2: By Formulation, Estimates & Trend Analysis
6.1. Market Share by Formulation, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Formulation:
6.2.1. Injectable Pen
6.2.2. Oral Tablet
6.2.3. Patch & Implant
Chapter 7. GLP-1 Drug Biosimilar Market Segmentation 3: By Distribution, Estimates & Trend Analysis
7.1. Market Share by Distribution, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Distribution:
7.2.1. Retail Pharmacy
7.2.2. Mail-Order & Specialty Pharmacy
7.2.3. Hospital & Clinic
Chapter 8. GLP-1 Drug Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global GLP-1 Drug Biosimilar Market, Regional Snapshot 2025 & 2035
8.2. North America
8.2.1. North America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Reference Biologic, 2022-2035
8.2.3. North America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2022-2035
8.2.4. North America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Distribution, 2022-2035
8.3. Europe
8.3.1. Europe GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Reference Biologic, 2022-2035
8.3.3. Europe GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2022-2035
8.3.4. Europe GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Distribution, 2022-2035
8.4. Asia Pacific
8.4.1. Asia Pacific GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Reference Biologic, 2022-2035
8.4.3. Asia Pacific GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2022-2035
8.4.4. Asia Pacific GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts By Distribution, 2022-2035
8.5. Latin America
8.5.1. Latin America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Reference Biologic, 2022-2035
8.5.3. Latin America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2022-2035
8.5.4. Latin America GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Distribution, 2022-2035
8.6. Middle East & Africa
8.6.1. Middle East & Africa GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Reference Biologic, 2022-2035
8.6.3. Middle East & Africa GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2022-2035
8.6.4. Middle East & Africa GLP-1 Drug Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Distribution, 2022-2035
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Teva Pharmaceuticals
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Biocon Biologics
9.2.3. amsung Bioepis
9.2.4. Sandoz
9.2.5. Sun Pharmaceutical
9.2.6. Dr. Reddy's Laboratories
9.2.7. Mylan (Viatris)
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
GLP 1 Drug Biosimilar Market Size is valued at USD 3.40 Bn in 2025 and is predicted to reach USD 86.23 Bn by the year 2035.
GLP 1 Drug Biosimilar Market is expected to grow at a 40.0% CAGR during the forecast period for 2026 to 2035.
Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Biocon Biologics Ltd., Celltrion Inc., Samsung Bioepis Co., Ltd., Viatris Inc., Amgen Inc., Dr. Reddy\'s Laboratories Ltd., Lupin Limited, Intas Pharmaceuticals Ltd., Alvotech, Bio-Thera Solutions Ltd., Organon & Co., Fresenius Kabi AG, Coherus BioSciences Inc., Dong-A ST Co., Ltd., Gan & Lee Pharmaceuticals, Hikma Pharmaceuticals PLC, Shanghai Henlius Biotech Inc., and Zhejiang Huahai Pharmaceutical Co., Ltd.
GLP 1 Drug Biosimilar Market is segmented into Reference Biologic, Formulation, Distribution, and By Region
North America region is leading the GLP 1 Drug Biosimilar Market.